drugset / Trial / NCT00659360

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

NCT00659360

Phase 2 Completed 17 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well AZD0530 works in treating patients with recurrent locally advanced, or metastatic soft tissue sarcoma. AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2008-02
Primary completion
2009-01
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject saracatinib Small molecule 175 mg Oral